One area of the market which I think has outstanding long term growth potential is the healthcare sector.
This is due to the growing demand for healthcare services globally because of ageing populations and increasing chronic disease burden.
In light of this, I think investing in the healthcare sector with a long term view could result in strong returns over the next decade.
Three healthcare shares that I would buy are listed below:
Cochlear Limited (ASX: COH)
One healthcare share to consider buying is Cochlear. It is a leading developer, manufacturer, and distributor of cochlear implantable devices for the hearing impaired globally. Its shares have provided market-beating returns for investors over the last decade and I believe it is well-placed to do the same over the next decade. This is thanks to its position as a leader in a structural growth market which has high barriers to entry and attractive demographics. According to the WHO, it has forecast there to be 1.5 billion people over the age of 65 by 2050, up from 524 million in 2010. I believe this bodes well for the company’s future growth.
CSL Limited (ASX: CSL)
Another healthcare share to consider buying is CSL. I believe the quality of the biotherapeutics company’s management team and its CSL Behring and Seqirus businesses means there’s a strong probability of its shares being market beaters again over the next 10 years. CSL Behring is the global leader in plasma therapies and Seqirus is the second biggest in the influenza vaccines industry. I feel both businesses have outstanding long-term growth prospects due to their leading products and potentially lucrative development pipelines.
Nanosonics Ltd (ASX: NAN)
Nanosonics is an infection control specialist which I think could be a great long term investment. It is best-known as the company behind the industry-leading trophon EPR disinfection system for ultrasound probes. While I think this product alone has the potential to underpin solid earnings growth over the coming years, I’m excited also by the upcoming launch of several new products targeting unmet needs. If these are half as successful as the trophon EPR disinfection system, then Nanosonics will have a very bright future.
And here are five more great options for 2020. All five have strong growth potential and trade at attractive prices at present.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.